



April 14, 2015

## **Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting**

TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with approved and developmental cancer immunotherapies and translation data in patients with lung cancer. Peregrine's lead PS-targeting antibody, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.

Abstract details:

### **[Abstract Number: 274](#)**

**Presentation Title:** Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer

**Presentation Time:** Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time

**Location:** Section 13

**Poster Board Number:** 2

**Author Block:** Soner Altio<sup>1</sup>, Melanie Mediavilla-Valera<sup>2</sup>, Jenny Krea<sup>2</sup>, David Noyes<sup>2</sup>, Tiffany N. Razabdouski<sup>2</sup>, Nikoletta L. Kallinteris<sup>3</sup>, Joseph Shan<sup>3</sup>, Scott Antonia<sup>2</sup>. <sup>1</sup>Nilogen Oncosystems, Tampa, FL; <sup>2</sup>Moffitt Cancer Center, Tampa, FL; <sup>3</sup>Peregrine Pharmaceuticals, Inc, Tustin, CA

### **[Abstract Number: 252](#)**

**Presentation Title:** Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models

**Presentation Time:** Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time

**Location:** Section 12

**Poster Board Number:** 10

**Author Block:** Bruce Freemark<sup>1</sup>, Jian Gong<sup>1</sup>, Dan Ye<sup>2</sup>, Rolf Brekken<sup>2</sup>, Shen Yin<sup>1</sup>, Jeff Hutchins<sup>1</sup>, Van Nguyen<sup>1</sup>, Chris Hughes<sup>3</sup>, Xianming Huang<sup>2</sup>. <sup>1</sup>Peregrine Pharmaceuticals, Inc, Tustin, CA; <sup>2</sup>UT Southwestern Medical Center, Dallas, TX; <sup>3</sup>University of California, Irvine, Irvine, CA

### **[Abstract Number: 4289](#)**

**Presentation Title:** Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors

**Presentation Time:** Tuesday, April 21, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time

**Location:** Section 24

**Poster Board Number:** 19

**Author Block:** Jian Gong, Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freemark. Peregrine Pharmaceuticals, Inc., Tustin, CA

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which

provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at [www.peregrineinc.com](http://www.peregrineinc.com).

CONTACT: Christopher Keenan

Peregrine Pharmaceuticals, Inc.

(800) 987-8256

[info@peregrineinc.com](mailto:info@peregrineinc.com)



Source: Peregrine Pharmaceuticals, Inc.

News Provided by Acquire Media